Summary
The effect of acarbose, an alpha-glucosidase inhibitor, on glycaemic control, was compared with placebo in a double-blind, randomised, group comparison study during 16 weeks in 20 non-obese non-insulin dependent diabetic patients in whom sulphonylurea treatment had been withdrawn.
There was significant deterioration in glycaemic control as assessed by HbA1 following withdrawal of the sulphonylurea. There was no significant improvement in HbA1 between weeks 0 and 16 in either the acarbose (11.3% and 12.4% respectively) or the placebo group (10.6% and 12.2% respectively). In both the acarbose and placebo treated groups fasting glucose and insulin concentrations were unaltered.
This study also suggests that acarbose was not an effective substitute for sulphonylureas in non-obese Type 2 diabetes uncontrolled by diet alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Puls W, Keup U, Krause HP, Thomas G (1977) Glucosidase inhibition: A new approach to the treatment of carbohydrate dependent metabolic disorders. Diabetologia 13: 426
Caspary WF (1978) Sucrose malabsorption in man after ingestion of alpha-glucosidase hydrolase inhibitor. Lancet 1: 1231
Sachse G, Willms B (1979) Effect of the alpha-glucosidase inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated and insulin-treated diabetics. Diabetologia 17: 287–290
Walton RJ, Sherif IT, Noy GA, Alberti KGMM (1979) Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidase inhibitor. Br Med J 1: 220–221
Uttenhall LO, Ukponmwan OO, Wood MS, Ghiglione M, Ghatei MA, Trayner IM, Bloom SR (1986) Long-term effects of intestinal alpha-glucosidase inhibition on post-prandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas. Diabetes Med 3: 155–160
Sachse G, Laube H, Maser H, Federlin K (1982) Effect of long-term acarbose therapy on the metabolic control of sulphonylurea-treated diabetic patients. Diabetologia 22: 221
Reid A, Tibi L, Smith AF (1980) Assessment of a simple method for measuring HbA1. Clin Chem Acta 108: 487–491
Heding LG (1975) Radioimmunological determination of human C-peptide in serum. Diabetologia 11: 541–548
Gerard J, Luyckx AS, Lefebvre PJ (1981) Improvement of metabolic control in insulin-dependent diabetics treated with the alpha-glucosidase inhibitor acarbose, for 2 months. Diabetologia 21: 446–451
McCulloch DK, Kurtz AB, Tattersall RB (1983) A new approach to the treatment of nocturnal hypoglycaemia using alpha-glucosidase inhibition. Diabetes Care 6: 483–487
Rosenkranz R, Hillebrand I, Boelime K, Bach I, Daweke H (1982) Improvement of carbohydrate metabolism by acarbose in maturity-onset diabetics not sufficiently treated with diet only. In: Creutzfeldt W (ed) Proceedings of the First International Symposium on Acarbose: Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam, pp 305–308
Schwedes U, Petzoldt R, Hillebrand I, Schoffling K (1982) Comparison of acarbose and metformin treatment in non-insulin dependent diabetic outpatients. In: Creutzfeldt W (ed) Proceedings of the First International Symposium on Acarbose: Effects on carbohydrate and fat metabolism. Excerpta Medica, Amsterdam, pp 275–281
Jenkins DJA, Taylor RH, Goff DH (1981) Scope and specificity of acarbose in slowing carbohydrate absorption in man. Diabetes 30: 951–954
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buchanan, D.R., Collier, A., Rodrigues, E. et al. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes. Eur J Clin Pharmacol 34, 51–53 (1988). https://doi.org/10.1007/BF01061417
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01061417